Union Bank of India will participate in the ‘Anand Rathi Annual Flagship Conference G-200 Summit’ investor conference on November 12, 2025. The conference is organized by Anand Rathi Share and Stock Brokers Limited. This announcement pertains to disclosures related to analysts/investors meet/call. Further details regarding the meeting are provided.

Investor Conference Participation

Union Bank of India has announced its participation in the ‘Anand Rathi Annual Flagship Conference G-200 Summit’, an investor conference organized by Anand Rathi Share and Stock Brokers Limited. The event is scheduled for November 12, 2025.

Meeting Details

The format of the meeting is a Group interaction. Registration for the meet will be conducted In-Person. Specific platform requirements will also be addressed In-Person.

Important Information

During the meeting, the bank will refer to publicly available documents. The bank has also stated that no unpublished price-sensitive information will be shared during the meeting/call.

This information is available on the bank’s website: https://www.unionbankofindia.co.in

Source: BSE

Trent Limited announces the availability of its presentation concerning the unaudited financial results (standalone and consolidated) for the second quarter (Q2) and half-year which ended on September 30, 2025. The investor presentation is accessible on the company’s website.

Investor Presentation Available

Trent Limited has made available its investor presentation detailing the unaudited financial results for Q2 (July-September) and the half-year ended on September 30, 2025. This presentation covers both standalone and consolidated financial performance.

Accessing the Presentation

Interested parties can view and download the investor presentation from the company’s website. The presentation provides insights into Trent Limited’s financial performance during the specified period.

Source: BSE

Hitachi Energy India has announced that the audio recording of its conference call with analysts and investors, held on November 7, 2025, is now available on the company’s website. The call took place from 16:30 to 17:30 hrs (IST). Interested parties can access the recording through the investor relations section of the Hitachi Energy India website.

Analyst Call Audio Recording

Hitachi Energy India has released the audio recording of its conference call with analysts and investors.

Details of the Recording

The conference call, which took place on November 7, 2025, from 16:30 to 17:30 hrs (IST), discussed key aspects of the company’s performance and strategy.

Accessing the Recording

The audio recording can be accessed on the Hitachi Energy India website in the investor relations section: https://www.hitachienergy.com/in/en/investor-relations/analyst-section.

Source: BSE

Torrent Pharmaceuticals has redeemed ₹100 crores of its Secured Redeemable Non-Convertible Debentures (NCDs). These NCDs were part of a larger issuance totaling ₹500 crores. The redemption was completed on November 7, 2025. This move reduces the company’s outstanding debt and reflects its strong financial management.

Partial Debenture Redemption

Torrent Pharmaceuticals announced the successful partial redemption of its Non-Convertible Debentures (NCDs) on November 7, 2025. The company redeemed a portion of its Secured Redeemable Non-Convertible Debentures.

Financial Details

The total value of NCDs redeemed amounted to ₹100 crores (Rupees One Hundred Crores). These debentures were part of a larger issuance, with the total NCDs issued amounting to ₹500 crores (Rupees Five Hundred Crores). The ISIN for these debentures is INE685A07124. This partial redemption indicates active capital management by Torrent Pharmaceuticals.

Source: BSE

Trent Limited announced strong financial results for Q2 (Jul-Sep) and H1 (Apr-Sep) FY26, with revenue growth of 17% and 19% respectively. Operating profit also saw significant increases of 16% and 23%. The company launched its new youth-focused fashion brand, ‘Burnt Toast’, expanding its portfolio, and continues to expand its store network across India.

Financial Performance Highlights

Trent Limited reported its financial results for the quarter and half-year ended September 30, 2025. Key highlights include:

• Q2 FY26 Revenue: ₹5,002 Cr, up 17%

• H1 FY26 Revenue: ₹10,063 Cr, up 19%

• Q2 FY26 Operating EBITDA: ₹575 Cr, up 16%

• H1 FY26 Operating EBITDA: ₹1,197 Cr, up 23%

• Q2 FY26 PAT: ₹451 Cr, up 6%

• H1 FY26 PAT: ₹873 Cr, up 14%

New Brand Launch

During the quarter, Trent launched ‘Burnt Toast’, targeting young, dynamic individuals. Initial customer response has been positive.

Store Network Expansion

Trent operates over 1000 large-format fashion stores across 251 cities. In Q2 FY26, 19 Westside and 44 Zudio stores were opened. As of September 30th, the store portfolio included 261 Westside, 806 Zudio and 34 stores across other lifestyle concepts, covering over 14 million sqft.

Consolidated Results Overview

The consolidated results reflect continued growth:

• Q2 FY26 Revenue: ₹5,107 Cr, up 16%

• H1 FY26 Revenue: ₹10,281 Cr, up 18%

• Q2 FY26 Operating EBITDA: ₹575 Cr, up 14%

• H1 FY26 Operating EBITDA: ₹1,212 Cr, up 20%

• Q2 FY26 PAT: ₹373 Cr, up 11%

• H1 FY26 PAT: ₹798 Cr, up 10%

Chairman’s Statement

Mr. Noel N Tata, Chairman, Trent Limited, stated that the company remains focused on portfolio growth, product elevation, and enhancing store experiences. He also noted the business registered steady performance during the quarter.

Source: BSE

AstraZeneca Pharma India Limited announced a 37% revenue growth for the quarter ended September 30, 2025, driven by strong performance in Oncology and Biopharmaceuticals. Revenue for Q2 2025-26 reached ₹5,590.9 million, and H1 2025-26 revenue totaled ₹10,854.0 million. The company also highlighted seven new approvals in H1, reinforcing its leadership across key therapy areas.

Financial Performance Overview

AstraZeneca Pharma India Limited reported a significant 37% revenue increase for Q2 2025-26. The company’s revenue for the quarter ending September 30, 2025, reached ₹5,590.9 million. Overall, H1 2025-26 revenue totaled ₹10,854.0 million. This growth reflects disciplined execution and strong momentum in key therapeutic areas.

Key Financial Highlights

Here is a summary of the company’s financial performance (in INR Mn):

Total revenue from Operations, Q2 2025: 5,590.9

Total revenue from Operations, H1 2025: 10,854.0

Total revenue from Operations, Q2 2024: 4,080.0

Total revenue from Operations, H1 2024: 7,955.2

Profit before exceptional item and tax, Q2 2025: 781.1

Profit before exceptional item and tax, H1 2025: 1531.7

Profit before exceptional item and tax, Q2 2024: 510.3

Profit before exceptional item and tax, H1 2024: 934.3

Profit after exceptional item and tax, Q2 2025: 542.2

Profit after exceptional item and tax, H1 2025: 1100.5

Profit after exceptional item and tax, Q2 2024: 384.3

Profit after exceptional item and tax, H1 2024: 266.4

Performance by Therapy Area

The company witnessed robust growth across its therapy areas:

Oncology, Q2 2025: 3,977.5

Oncology, H1 2025: 7,673.6

Biopharmaceuticals (CVRM, R&I and V&I), Q2 2025: 1,267.5

Biopharmaceuticals (CVRM, R&I and V&I), H1 2025: 2,457.5

Rare Disease, Q2 2025: 38.1

Rare Disease, H1 2025: 42.3

New Drug Approvals and Milestones

AstraZeneca highlighted several key regulatory approvals and milestones including:

• Durvalumab: Received approval for additional indications in endometrial cancer treatment.
• Launched Eculizumab for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
• Osimertinib: Received approval for use in combination with chemotherapy for first-line treatment of NSCLC.
• Trastuzumab deruxtecan: Received approval for an additional indication in HER2-low and HER2-ultralow metastatic breast cancer patients.
• Osimertinib: Approval for monotherapy treatment of NSCLC.
• Benralizumab: Approval as an add-on treatment for EGPA.

Source: BSE

Aegis Logistics announces the availability of the audio recording of its earnings call discussing the unaudited financial results for the quarter and six months ended September 30, 2025. The call was held on November 07, 2025, at 2.30 p.m. (IST). The audio recording is accessible on the company’s website under the Investor Presentations section.

Earnings Call Recording Available

Aegis Logistics has released the audio recording of its earnings call pertaining to the unaudited financial results. This call covered the company’s performance for the quarter and six months period, which concluded on September 30, 2025.

Accessing the Recording

The earnings call, which took place on November 07, 2025, at 2.30 p.m. (IST), is now available for replay. Interested parties can access the audio recording through the Aegis Logistics website. The recording is located in the Investor Presentations section of the site.

Source: BSE

Ramkrishna Forgings announced that the National Company Law Tribunal (NCLT), Kolkata Bench, has approved the Second Motion Petition Order regarding the Scheme of Amalgamation. This scheme involves Mal Metalliks Private Limited and Multitech Auto Private Limited with Ramkrishna Casting Solutions Limited. The approval was granted on November 6, 2025, following the hearing on October 7, 2025.

Amalgamation Scheme Receives Approval

Ramkrishna Forgings has received a favorable order from the Hon’ble National Company Law Tribunal (NCLT), Kolkata Bench, concerning the proposed Scheme of Amalgamation. The approval pertains to the merger of Mal Metalliks Private Limited and Multitech Auto Private Limited into Ramkrishna Casting Solutions Limited.

Details of the Amalgamation

The Scheme of Amalgamation involves Mal Metalliks Private Limited, a step-down wholly-owned subsidiary, and Multitech Auto Private Limited, a wholly-owned subsidiary, merging with Ramkrishna Casting Solutions Limited, which is also a wholly-owned subsidiary of Ramkrishna Forgings. This decision follows earlier intimations on February 22, 2024, and September 05, 2025.

Tribunal’s Order

The Hon’ble National Company Law Tribunal, Kolkata Bench, heard the Second Motion Petition on October 07, 2025. The order, which was uploaded on the website of Hon’ble Tribunal on November 06, 2025, has officially allowed the Second Motion Petition filed. A copy of the order has been made available on the company website.

Source: BSE

Samvardhana Motherson International Limited has established the Motherson ESOP Trust to manage its employee stock option scheme. The trust, formed with an initial corpus of ₹10,000, will oversee the administration and implementation of the Samvardhana Motherson International Limited Employees Stock Option Scheme 2025. The trust aims to benefit employees by managing and transferring shares under the scheme, contributing to employee welfare and retention.

Motherson ESOP Trust Establishment

Samvardhana Motherson International Limited (Motherson) announced the establishment of the Motherson ESOP Trust, an irrevocable trust, to administer and implement its employee stock option scheme. The decision was formalized on November 7, 2025.

Trust Purpose and Management

The primary purpose of the Motherson ESOP Trust is to manage the Samvardhana Motherson International Limited Employees Stock Option Scheme 2025. The trust will acquire shares of the company through primary issuance or secondary acquisition and transfer shares to beneficiaries as per the scheme’s terms. The trust aims to foster employee benefits and manage equity-based compensation plans.

Trust Structure

The trust was established with an initial corpus of ₹10,000. The trustees will administer the trust property and ensure the welfare of the beneficiaries by dealing in movable and immovable assets according to the scheme. Arjun Puri and Gautam Mukherjee have been appointed as trustees. The trustees will hold the trust fund and apply it to carry out the provisions of the Scheme as defined in the Trust Deed.

Key Provisions of the Trust

The trust is irrevocable and will continue until specific events such as the winding-up of the Settlor or the termination of the trust. The trustees have powers to manage the trust, administer the scheme, and acquire shares. Additionally, the trust ensures compliance with applicable laws and guidelines, including insider trading regulations and code of conduct. The trust will refrain from entering into any derivatives contracts. The board also reserves the right to amend or alter the scheme, provided such changes do not harm the beneficiaries.

Benefits to Employees

The establishment of the Motherson ESOP Trust enables Samvardhana Motherson International Limited to attract, retain, and incentivize employees. The trust allows employees to benefit from the company’s growth through equity participation, fostering a sense of ownership and alignment with the company’s success.

Source: BSE